661 related articles for article (PubMed ID: 22258483)
1. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
[TBL] [Abstract][Full Text] [Related]
2. Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.
Manwatkar A; Padiyar S; Nair A; Jha A; Kumar S; Yadav B; Prakash JAJ; Das JK; Mathew J
Clin Rheumatol; 2023 Dec; 42(12):3289-3297. PubMed ID: 37801141
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy.
Kaji K; Fujimoto M; Hasegawa M; Kondo M; Saito Y; Komura K; Matsushita T; Orito H; Hamaguchi Y; Yanaba K; Itoh M; Asano Y; Seishima M; Ogawa F; Sato S; Takehara K
Rheumatology (Oxford); 2007 Jan; 46(1):25-8. PubMed ID: 16728436
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to DNA mismatch repair enzymes in polymyositis/dermatomyositis and other autoimmune diseases: a possible marker of favorable prognosis.
Muro Y; Nakashima R; Hosono Y; Sugiura K; Mimori T; Akiyama M
Arthritis Rheumatol; 2014 Dec; 66(12):3457-62. PubMed ID: 25186186
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of the clinical picture and serologic profile in patients with dermatomyositis and polymyositis coexisting with neoplastic disease].
Bobrowska-Snarska D; Ostanek L; Brzosko M
Ann Acad Med Stetin; 2011; 57(2):32-8. PubMed ID: 23002666
[TBL] [Abstract][Full Text] [Related]
6. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study.
Huang YL; Chen YJ; Lin MW; Wu CY; Liu PC; Chen TJ; Chen YC; Jih JS; Chen CC; Lee DD; Chang YT; Wang WJ; Liu HN
Br J Dermatol; 2009 Oct; 161(4):854-60. PubMed ID: 19558555
[TBL] [Abstract][Full Text] [Related]
7. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2.
Ishikawa A; Muro Y; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Jul; 51(7):1181-7. PubMed ID: 22427409
[TBL] [Abstract][Full Text] [Related]
8. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
9. Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts.
Zhong L; Yu Z; Song H
Clin Immunol; 2019 Jan; 198():11-18. PubMed ID: 30445156
[TBL] [Abstract][Full Text] [Related]
10. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
11. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.
Hengstman GJ; Brouwer R; Egberts WT; Seelig HP; Jongen PJ; van Venrooij WJ; van Engelen BG
J Neurol; 2002 Jan; 249(1):69-75. PubMed ID: 11954871
[TBL] [Abstract][Full Text] [Related]
12. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.
Srivastava P; Dwivedi S; Misra R
Rheumatol Int; 2016 Jul; 36(7):935-43. PubMed ID: 27193471
[TBL] [Abstract][Full Text] [Related]
13. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
15. Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash.
Ichimura Y; Konishi R; Shobo M; Inoue S; Okune M; Maeda A; Tanaka R; Kubota N; Matsumoto I; Ishii A; Tamaoka A; Shimbo A; Mori M; Morio T; Kishi T; Miyamae T; Tanboon J; Inoue M; Nishino I; Fujimoto M; Nomura T; Okiyama N
Rheumatology (Oxford); 2022 Mar; 61(3):1222-1227. PubMed ID: 34152410
[TBL] [Abstract][Full Text] [Related]
16. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
17. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis.
Aouizerate J; De Antonio M; Bader-Meunier B; Barnerias C; Bodemer C; Isapof A; Quartier P; Melki I; Charuel JL; Bassez G; Desguerre I; Gherardi RK; Authier FJ; Gitiaux C
Rheumatology (Oxford); 2018 May; 57(5):873-879. PubMed ID: 29474663
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature.
Xu Y; Ma X; Zhou Z; Li J; Hou J; Zhu J; Kang M; Lai J; Li X
Pediatr Rheumatol Online J; 2021 Jan; 19(1):2. PubMed ID: 33407602
[TBL] [Abstract][Full Text] [Related]
19. The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis.
Yin L; Ge Y; Yang H; Peng Q; Lu X; Zhang Y; Wang G
Clin Rheumatol; 2016 Nov; 35(11):2715-2721. PubMed ID: 27502600
[TBL] [Abstract][Full Text] [Related]
20. Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options.
Fredi M; Bartoli F; Cavazzana I; Ceribelli A; Carabellese N; Tincani A; Satoh M; Franceschini F
Clin Exp Rheumatol; 2017; 35(2):303-308. PubMed ID: 27908312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
